Back to Search
Start Over
Sorafenib in hepatocellular carcinoma.
- Source :
-
British journal of hospital medicine (London, England : 2005) [Br J Hosp Med (Lond)] 2010 Aug; Vol. 71 (8), pp. 451-6. - Publication Year :
- 2010
-
Abstract
- Sorafenib, a small molecule multikinase inhibitor, is the standard of care in the USA and Europe for the treatment of advanced hepatocellular carcinoma. This article reviews its development from the basis of molecular hepatocarcinogenesis to phase III trials and discusses the future for sorafenib in hepatocellular carcinoma.
- Subjects :
- Carcinoma, Hepatocellular etiology
Carcinoma, Hepatocellular pathology
Humans
Liver Neoplasms etiology
Liver Neoplasms pathology
Neoplasm Staging methods
Niacinamide analogs & derivatives
Phenylurea Compounds
Sorafenib
Treatment Outcome
Antineoplastic Agents therapeutic use
Benzenesulfonates therapeutic use
Carcinoma, Hepatocellular drug therapy
Liver Neoplasms drug therapy
Protein Kinase Inhibitors therapeutic use
Pyridines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1750-8460
- Volume :
- 71
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- British journal of hospital medicine (London, England : 2005)
- Publication Type :
- Academic Journal
- Accession number :
- 20852487
- Full Text :
- https://doi.org/10.12968/hmed.2010.71.8.77669